Last updated: February 19, 2026
This analysis examines Australian patent AU2002340670, titled "ANTI-IGF-1 RECEPTOR ANTIBODIES AND USES THEREOF." The patent, filed by ImClone Systems Incorporated on June 17, 2002, and granted on October 13, 2005, protects antibodies targeting the Insulin-like Growth Factor 1 Receptor (IGF-1R) and their therapeutic applications, primarily in treating cancers. The patent has expired.
What is the Core Technology Protected by AU2002340670?
The patent protects novel antibodies that bind to the IGF-1R. This receptor is a key component of the IGF signaling pathway, which plays a critical role in cell growth, proliferation, and survival. Dysregulation of this pathway is implicated in the development and progression of various cancers. The antibodies claimed are designed to inhibit the activity of IGF-1R, thereby interfering with cancer cell growth.
The patent covers:
- Specific Antibody Sequences: Claims delineate the amino acid sequences of variable regions (light and heavy chains) of specific antibodies, designated as hMK-1 and hMK-8. These sequences are central to the antibody's binding specificity and efficacy.
- Antibody Variants: It also claims modified forms of these antibodies, including chimeric, humanized, and human antibodies. This broadens protection to encompass different engineering approaches to antibody development.
- Fusion Proteins: The patent includes claims for fusion proteins comprising an IGF-1R binding domain. This allows for the development of more complex therapeutic modalities.
- Pharmaceutical Compositions: It protects pharmaceutical formulations containing the claimed antibodies, designed for effective delivery and administration.
- Methods of Treatment: The patent claims methods of treating or preventing IGF-1R-mediated diseases, particularly cancers, using the novel antibodies. This includes specific cancers such as lung, breast, prostate, colon, and ovarian cancers, among others.
What Are the Key Claims of AU2002340670?
The patent's claims define the boundaries of intellectual property protection. For AU2002340670, the critical claims relate to the structure of the antibodies and their therapeutic use.
Independent Claims of Significance:
- Claim 1: Claims a humanized monoclonal antibody that binds to an epitope on the human IGF-1 receptor, wherein the antibody comprises a heavy chain and a light chain, and wherein the variable regions of the antibody are derived from antibodies hMK-1 or hMK-8. This claim is foundational, defining the core antibody structure and its origin.
- Claim 7: Claims a pharmaceutical composition comprising an antibody according to any one of claims 1 to 6 and a pharmaceutically acceptable carrier. This claim broadens the protection to include formulations, essential for drug development and commercialization.
- Claim 17: Claims a method of treating a proliferative disorder in a subject, comprising administering to the subject an effective amount of an antibody according to any one of claims 1 to 6. This claim establishes the therapeutic utility and market application of the patented antibodies.
- Claim 18: Claims a method of inhibiting IGF-1 receptor activity in a subject, comprising administering to the subject an effective amount of an antibody according to any one of claims 1 to 6. This claim protects the mechanism of action.
Dependent Claims: These claims further refine the scope by specifying particular antibody formats, modified sequences, and specific therapeutic indications. For instance, they might detail specific CDR (Complementarity-Determining Region) sequences or specify the use against particular cancer types.
Claim Interpretation: The claims are interpreted to protect antibodies that exhibit specific binding characteristics to IGF-1R and are designed for therapeutic intervention in diseases driven by this receptor. The focus is on the antibody itself and its application, rather than the IGF-1R target in isolation.
How Does AU2002340670 Sit Within the Broader IGF-1R Antibody Patent Landscape?
The patent AU2002340670 was filed during a period of significant research and development in targeted cancer therapies, particularly in the field of monoclonal antibodies. The IGF-1R pathway was recognized as a promising target for oncology.
Key Players and Technologies in the IGF-1R Landscape (Early 2000s):
- Early Research: Initial discoveries identifying the role of IGF-1R in cancer preceded this patent.
- Antibody Engineering: Advancements in antibody engineering (chimerization, humanization) allowed for the development of more potent and less immunogenic therapeutics, as reflected in the claims of AU2002340670.
- Competitors: Companies like Pfizer, Sanofi-Aventis, and Novartis were also active in researching IGF-1R inhibitors. These could include small molecules or other antibody-based approaches.
- Clinical Development: Several IGF-1R antibodies entered clinical trials around the time of this patent's filing and grant. These antibodies, if patented, would represent potential competitors or alternative approaches.
- Patent Filings: A surge in patent filings related to IGF-1R antibodies and their uses was observed during this period. AU2002340670 is one of many patents that collectively define the IP landscape.
Post-AU2002340670 Landscape Evolution:
- Regulatory Approvals: The success or failure of other IGF-1R antibodies in clinical trials and regulatory review influenced subsequent investment and research focus.
- Combination Therapies: Research shifted towards combining IGF-1R inhibitors with other cancer treatments, leading to new patenting strategies.
- Emerging Targets: As the complexity of cancer biology became clearer, other signaling pathways and targets gained prominence, diversifying the therapeutic landscape.
AU2002340670's expiration on June 17, 2022, has now removed the primary patent barrier to the specific antibodies it claimed. However, related patents concerning formulations, manufacturing processes, or novel uses might still be in effect.
What Were the Potential Business and R&D Implications of AU2002340670?
The patent granted ImClone Systems Incorporated exclusive rights to its IGF-1R antibodies in Australia for the patent term. This had significant implications for R&D and business strategy.
For ImClone Systems (and potential licensees):
- Market Exclusivity: The patent provided a period of market exclusivity, allowing for potential return on R&D investment through licensing or direct commercialization.
- Strategic Partnerships: The patent served as a valuable asset for seeking partnerships or collaborations with larger pharmaceutical companies for clinical development and marketing.
- Licensing Revenue: ImClone could have generated revenue through licensing the technology to other entities.
- R&D Focus: The patent defined a specific area of therapeutic development, guiding internal R&D efforts.
For Competitors and Generic Manufacturers:
- Freedom to Operate (FTO) Analysis: Competitors and generic manufacturers would have conducted thorough FTO analyses to assess the risk of infringing on AU2002340670 and other related patents before investing in similar technologies or products.
- Circumvention Strategies: Competitors might have focused on developing antibodies with different epitopes on the IGF-1R, or alternative mechanisms of action, to avoid infringement.
- Post-Expiration Opportunities: The eventual expiration of the patent opened the door for generic development and market entry, assuming no other relevant patents remained active.
For Investors:
- Asset Valuation: The patent represented a tangible intellectual property asset, contributing to the valuation of ImClone Systems.
- Risk Assessment: Investors would have assessed the strength and breadth of the patent claims, as well as the potential for invalidation or infringement challenges.
- Market Potential: The patent's scope concerning therapeutic applications provided an indication of the potential market size for IGF-1R targeted therapies.
What is the Status of AU2002340670 and Related Intellectual Property?
Australian patent AU2002340670 expired on June 17, 2022. This means the core claims related to the specific antibodies hMK-1 and hMK-8, as defined in the patent, are no longer protected in Australia.
Key Status Points:
- Expiration Date: June 17, 2022.
- Current Protection: None for the original claims.
- Post-Expiration Considerations:
- Manufacturing: Entities are now free to manufacture and sell products embodying the claims of AU2002340670, provided they do not infringe on any other still-active patents.
- New Therapies: Research and development of novel IGF-1R antibodies or related technologies are not precluded by this expired patent.
- Related Patents: It is crucial to investigate whether related patent families filed by ImClone Systems or its successors for the same or similar inventions, or for specific formulations, manufacturing processes, or new therapeutic uses, are still active in Australia or other jurisdictions. These could still present barriers to market entry or require licensing.
- Portfolio Analysis: A comprehensive analysis of ImClone Systems' (or its successor's) entire patent portfolio related to IGF-1R therapies is necessary for a complete understanding of the ongoing IP landscape.
Conclusion
Patent AU2002340670 played a role in defining the early intellectual property landscape for IGF-1R targeted antibodies in Australia. Its claims provided protection for specific antibody sequences and their therapeutic uses, particularly in oncology. The patent's expiration removes a significant barrier for potential generic development and further research into this class of therapeutics. However, a thorough examination of any remaining related patents is essential for any party seeking to enter or operate within this therapeutic space.
Key Takeaways
- Australian patent AU2002340670 protected specific humanized monoclonal antibodies targeting the Insulin-like Growth Factor 1 Receptor (IGF-1R) and their use in treating cancers.
- The patent's core claims covered antibody sequences (hMK-1, hMK-8), pharmaceutical compositions, and methods of treatment for proliferative disorders.
- AU2002340670 expired on June 17, 2022, removing its exclusive protection for the claimed inventions in Australia.
- The expiration opens avenues for generic development and further research, subject to any other active related patents.
Frequently Asked Questions
-
Can I now freely develop and sell generic versions of the antibodies claimed in AU2002340670 in Australia?
While the patent AU2002340670 has expired, you must confirm that your proposed product does not infringe on any other currently active patents held by the original assignee or other entities. This includes patents covering specific formulations, manufacturing processes, or novel therapeutic indications.
-
What was the primary therapeutic target of the antibodies protected by AU2002340670?
The primary therapeutic target was the Insulin-like Growth Factor 1 Receptor (IGF-1R), a key signaling molecule implicated in cancer cell growth and survival.
-
Did this patent cover small molecule inhibitors of IGF-1R?
No, AU2002340670 specifically protected monoclonal antibodies and fusion proteins designed to bind to and inhibit IGF-1R. It did not cover small molecule inhibitors.
-
Who was the original applicant for patent AU2002340670?
The original applicant was ImClone Systems Incorporated.
-
Are there any other Australian patents still active that might cover similar IGF-1R antibodies?
A comprehensive search of the Australian patent register is required to determine if other related patents, potentially covering different aspects or later developments of IGF-1R antibodies by the same or other entities, remain active.
Cited Sources
[1] ImClone Systems Incorporated. (2005). ANTI-IGF-1 RECEPTOR ANTIBODIES AND USES THEREOF. Australian Patent AU2002340670. (Original filing date: June 17, 2002; Grant date: October 13, 2005; Expiration date: June 17, 2022).
